Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 14/20 | 0.60 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.60 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MDH2 | P40926 | 2/20 | 0.55 |
| ▸ | MDH1 | P40925 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083023 | 1.00 | MEN1 (0.76) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL16158225 | 0.86 | MEN1 (0.74) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL419725 | 0.85 | MEN1 (0.63) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL417133 | 0.84 | MEN1 (0.62) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL25860073 | 0.83 | MEN1 (0.54) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL417009 | 0.82 | RAB9A (0.53) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| Hydrochloric Acid SCHEMBL11702177 | 0.82 | MEN1 (0.63) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL11706453 | 0.82 | MEN1 (0.60) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL14829104 | 0.82 | MEN1 (0.68) | MEN1KMT2ARAB9AHIF1AEPAS1 | |
| SCHEMBL14829261 | 0.81 | MEN1 (0.67) | MEN1KMT2ARAB9AHIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3933835-A | ANTIALLERGENS, HYPOLIPIDAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | claimed |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-05-19 | — | — | US | disclosed |
| CN-117843590-A | 3-amino-4- (piperazin-1-yl) benzamide derivative, pharmaceutical composition containing same, and preparation method and application thereof | 中国药科大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-110776892-A | Microemulsion neutral blocking remover | 西安中孚凯宏石油科技有限责任公司 | 2020-02-11 | — | — | CN | disclosed |
| US-20200031764-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2020-01-30 | — | — | US | disclosed |
| US-20180356421-A9 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | UNIV YALE (US) | 2018-12-13 | — | — | US | disclosed |
| US-10145848-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018164549-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 동국대학교 산학협력단 | 2018-09-13 | — | — | WO | disclosed |
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| WO-2012078559-A2 | SMALL-MOLECULE HYDROPHOBIC TAGGING OF FUSION PROTEINS AND INDUCED DEGRADATION OF SAME | YALE UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012053768-A2 | ARYLOXYPHENOXYACETYL-BASED COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-26 | — | — | WO | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20100172844-A1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | PHILOCHEM AG (CH) | 2010-07-08 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| WO-2008004798-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-01-10 | — | — | WO | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031764-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | MDH2, MDH1, ALDH5A1 | MEN1 1274/4885KMT2A 1497/4885RAB9A 2374/4885 |
| US-20180356421-A9 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | MEN1 2899/4885KMT2A 3767/4885RAB9A 976/4885 |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | MDH2, MDH1, ME2 | MEN1 1609/4885KMT2A 658/4885RAB9A 2748/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | MEN1 3151/4885KMT2A 2118/4885RAB9A 2181/4885 |
| US-10145848-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | HSP90B1, LAMP2, PSMG3 | MEN1 2899/4885KMT2A 3767/4885RAB9A 976/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | MEN1 844/4885KMT2A 4433/4885RAB9A 2650/4885 |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | MEN1 3620/4885KMT2A 1390/4885RAB9A 884/4885 |
| US-20100172844-A1 | ALBUMIN BINDING MOLECULES AND USES THEREOF | ALB, FABP1, FABP2 | MEN1 4531/4885KMT2A 4806/4885RAB9A 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.